Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.
about
Antiviral prophylaxis for varicella zoster in immunocompromised patients (excluding haematological malignancies)Antiviral prophylaxis for varicella zoster in immunocompromised patients (excluding haematological malignancies)Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspectiveProphylactic Measures During Induction for Acute Myeloid Leukemia.Epidemiology and potential preventative measures for viral infections in children with malignancy and those undergoing hematopoietic cell transplantationLate effects of blood and marrow transplantation.Varicella zoster virus infection after allogeneic hematopoietic cell transplantation in children using a relatively short duration of acyclovir prophylaxis: A retrospective study.Incidence and risk factors for herpes zoster following heart transplantation.Oral lesions and lymphoproliferative disorders.Organ-specific management and supportive care in chronic graft-versus-host disease.Herpes simplex and varicella zoster viruses: forgotten but not gone.Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulinValganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trialVaricella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation.Zeroing in on zoster: A tale of many disorders produced by one virusNational Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report.Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.High incidence of herpes zoster in nonmyeloablative hematopoietic stem cell transplantation.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation.Aciclovir and varicella-zoster-immunoglobulin in solid-organ transplant recipients.Managing fungal and viral infections in pediatric leukemia.Management of multidrug-resistant viruses in the immunocompromised host.Varicella zoster virus meningoencephalitis after allogeneic hematopoietic stem cell transplantation.Using antimicrobial adjuvant therapy in cancer treatment: a review.Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challengePretransplant vaccinations in allogeneic stem cell transplantation donors and recipients: an often-missed opportunity for immunoprotection?National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.Prevention of viral infections in patients with multiple myeloma: the role of antiviral prophylaxis and immunization.Predicting risk factors for varicella zoster virus infection and postherpetic neuralgia after hematopoietic cell transplantation using ordered logistic regression analysis.Herpes Zoster in Autologous Hematopoietic Cell Transplant Recipients in the Era of Acyclovir or Valacyclovir Prophylaxis and Novel Treatment and Maintenance Therapies.Herpes zoster after autologous hematopoietic stem cell transplantation.The yield of monitoring for HSV and VZV viremia in pediatric hematopoietic stem cell transplant patients.T Cell Immunity to Varicella-Zoster Virus in the Setting of Advanced HIV and Multiple Varicella-Zoster Virus Recurrences.Brincidofovir treatment of acyclovir-resistant disseminated varicella zoster virus infection in an immunocompromised host.Varicella zoster virus reactivation after autologous SCT is a frequent event and associated with favorable outcome in myeloma patients.Varicella zoster virus encephalomyelitis as a late complication following haematopoietic stem cell transplantation.A Japanese single-hospital observational trial with a retrospective case-control analysis of varicella zoster virus reactivation after autologous peripheral blood stem cell transplantation.Herpes zoster incidence and cost in patients receiving autologous hematopoietic stem-cell transplant.
P2860
Q24186915-03528CD5-44F7-4594-AC42-34FAA3B314CBQ24240987-7C40EC30-50B3-47E6-92E8-5766CE12AA8EQ28388806-033CF871-2F83-4B05-AECB-6BC2F1F87F91Q30235496-CC71EB72-DE98-4772-895F-67A6B52EF0FFQ33559473-D90BBE40-96F9-40C4-A20B-8E207490F2D9Q33574136-03C743A6-3ACC-4EC7-83CD-3A161C6E67D1Q33621313-B24B276B-D9F6-4DE8-8194-9C313DFE5AF4Q33637650-322954C8-535F-4D43-B601-7AD861F077D8Q34127648-F8A20AFC-6676-477E-84E4-7C7A2462BEBFQ34270868-205F8531-CD75-4014-A861-A535092D5FA0Q34613055-9DA599EF-D653-4898-953B-A25E717AA5B3Q35190671-A0B641F1-312A-48B3-B13B-AD05F09F90DCQ35735525-4FABBF1B-2B65-4DC2-B22F-0C7555F930D9Q36006384-92E666BA-0F81-4479-B0D2-D5CC6E5BB52DQ36236794-650CA3D8-0397-42CB-B4B2-609BA164C91EQ36766324-9AEC546B-3AD6-47D9-9DF7-B03BF5F0A9A0Q37150434-442619D0-C4FA-4A79-9434-B00C09AD3E84Q37182608-C00211CD-4CCD-4F58-B39D-22364AA84309Q37426542-A9FC84D4-B189-4D84-8933-551A8423CC71Q37453850-F52473F7-BE92-4628-9961-DC53113FDC03Q37559627-EBD8CF72-CADB-42CF-9EF4-C420A7AEE75CQ37809492-21D66047-3170-4E03-9809-E48A895B3B53Q37810281-010C51D5-616D-449A-9A9C-86A6AA65E761Q37970424-B795F88C-28EF-4540-B657-A3B956494B83Q37984818-07B00A7E-D3DE-4955-B66E-F4BE958E1439Q38060894-476722D6-E02E-4EE4-8F2E-0087D293F97CQ38066877-C7918CD7-86E0-4718-B3E5-3BF3F3188F5DQ38387297-2B112211-F7B2-4B0C-886D-1778B6510434Q38405199-5FF6E7A9-FE98-476B-A3B7-E9FA5EAC80D2Q38613285-806B92FE-63CD-42F9-99E8-DFE27D6F3FC8Q39023136-2E8D1E50-454E-4B80-ADD6-CAC24843FD0DQ39063520-FFE13BA5-D842-4124-AAE4-7FF5EE12058DQ39173692-A998C576-02AC-4FBD-B84E-A037A9891AD7Q40148526-BD01BF1F-B3BA-4779-8FE9-19EE2C0B1F39Q40442389-EBB77D93-E4B9-4972-8E40-92E40543D499Q40592185-78D7B586-4E2C-41E4-AE30-6C61D3356160Q41535668-81431C7D-39D7-4AE7-A0BF-B7991620D510Q41589366-EE440797-8A60-44F5-B9BD-4EF737C25EF5Q41695426-E8D1F41B-1312-4CB2-9198-37265AA7B9CEQ41930857-DC62ACDB-7787-4E49-8C65-1DD1FF582175
P2860
Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Long-term acyclovir for preven ...... lind placebo-controlled study.
@ast
Long-term acyclovir for preven ...... lind placebo-controlled study.
@en
type
label
Long-term acyclovir for preven ...... lind placebo-controlled study.
@ast
Long-term acyclovir for preven ...... lind placebo-controlled study.
@en
prefLabel
Long-term acyclovir for preven ...... lind placebo-controlled study.
@ast
Long-term acyclovir for preven ...... lind placebo-controlled study.
@en
P2093
P2860
P1433
P1476
Long-term acyclovir for preven ...... lind placebo-controlled study.
@en
P2093
Hyung W Kim
Joel D Meyers
Mary E D Flowers
Raleigh A Bowden
P2860
P304
P356
10.1182/BLOOD-2005-09-3624
P407
P577
2005-11-10T00:00:00Z